Get it on Google Play

Arrowhead drug cuts tau levels 73% in early trial data

October 14, 2026 7:30 AM EDT Send to a Friend
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported interim Phase 1/2a clinical data for ARO-MAPT, its investigational RNA interference (RNAi) therapy targeting tau ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login